Editor’s Note, SGLT2-Inhibitor Special Edition, July 2014

When the first SGLT-2 inhibitor came to the market we went to doctors all over the country and asked them their opinions on this new class of drugs. The overwhelming response was "wait and see." Now a year later we asked them again to tell us how they feel about this class of drugs. This month we have some of their "newer opinions" to share with you.